Down syndrome (DS), characterised by compromised brain development and intellectual challenges, often manifests Alzheimer's disease (AD) -like symptoms. Utilising the Web of Science Core Collection (WOSCC) database from January 1, 2000, to July 31, 2023, we conducted a comprehensive bibliometric analysis using VOSviewer, CiteSpace, and the R package “bibliometrix.” Analyses included co-authorship, co-citation, co-occurrence, cooperative network, reference, and keyword burst citation. Analysing 5,082 papers, the U.S. demonstrated prominence with the highest number of research organisations and citations. Keyword analysis revealed promising research areas, including “Alzheimer's disease,” “development,” “inflammation,” and “neurogenesis”. This 22-year survey of the brain with trisomy 21 research unveils key trends, contributors, and focal areas in DS neuropathogenesis. Notably, Alzheimer ’s-related genes and proteins play a pervasive role in DS neuropathological processes across patients' lifespans. The study contributes foundational knowledge for advancing research and care in the DS neuropathogenesis domain.
AhmedMdMJohnsonNRBoydTD, et al. (2021) Innate Immune System Activation and Neuroinflammation in Down Syndrome and Neurodegeneration: Therapeutic Targets or Partners?Frontiers in Aging Neuroscience13: 718426.
2.
Alzheimer’s & dementia (2022) 2022 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association18(4): 700–789.
3.
AmaralPPLeonardiTHanN, et al. (2018) Genomic positional conservation identifies topological anchor point RNAs linked to developmental loci. Genome Biology19(1): 32.
4.
Andrade-GuerreroJSantiago-BalmasedaAJeronimo-AguilarP, et al. (2023) Alzheimer’s Disease: An Updated Overview of Its Genetics. International Journal of Molecular Sciences24(4): 3754.
5.
AntonarakisSELyleRDermitzakisET, et al. (2004) Chromosome 21 and Down syndrome: from genomics to pathophysiology. Nature Reviews Genetics5(10): 725–738.
6.
AntonarakisSESkotkoBGRafiiMS, et al. (2020) Down syndrome. Nature Reviews. Disease Primers6(1): 9.
7.
ArenaAIyerAMMilenkovicI, et al. (2017) Developmental Expression and Dysregulation of miR-146a and miR-155 in Down’s Syndrome and Mouse Models of Down’s Syndrome and Alzheimer’s Disease. Current Alzheimer Research14(12): 1305–1317.
8.
AylwardEHLiQHoneycuttNA, et al. (1999) MRI volumes of the hippocampus and amygdala in adults with Down’s syndrome with and without dementia. The American Journal of Psychiatry156(4): 564–568.
9.
Bernabeu-ZornozaACoronelRPalmerC, et al. (2019) Physiological and pathological effects of amyloid-β species in neural stem cell biology. Neural Regeneration Research14(12): 2035–2042.
10.
BullMJ (2020) Down Syndrome. The New England Journal of Medicine382(24): 2344–2352.
11.
BystronIBlakemoreCRakicP (2008) Development of the human cerebral cortex: Boulder Committee revisited. Nature Reviews. Neuroscience9(2): 110–122.
12.
CanzonettaCMulliganCDeutschS, et al. (2008) DYRK1A-Dosage Imbalance Perturbs NRSF/REST Levels, Deregulating Pluripotency and Embryonic Stem Cell Fate in Down Syndrome. American Journal of Human Genetics83(3): 388–400.
13.
ChapmanRSHeskethLJ (2000) Behavioral phenotype of individuals with Down syndrome. Mental Retardation and Developmental Disabilities Research Reviews6(2): 84–95.
14.
ChenCJiangPXueH, et al. (2014) Role of astroglia in Down’s syndrome revealed by patient-derived human-induced pluripotent stem cells. Nature Communications5: 4430.
15.
ChenYYuY (2023) Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation. Journal of Neuroinflammation20(1): 165.
16.
ColonnaMButovskyO (2017) Microglia Function in the Central Nervous System During Health and Neurodegeneration. Annual Review of Immunology35: 441–468.
17.
CoronelRLachgarMBernabeu-ZornozaA, et al. (2019a) Neuronal and Glial Differentiation of Human Neural Stem Cells Is Regulated by Amyloid Precursor Protein (APP) Levels. Molecular Neurobiology56(2): 1248–1261.
18.
CoronelRPalmerCBernabeu-ZornozaA, et al. (2019b) Physiological effects of amyloid precursor protein and its derivatives on neural stem cell biology and signaling pathways involved. Neural Regeneration Research14(10): 1661–1671.
19.
DonthuNKumarSMukherjeeD, et al. (2021) How to conduct a bibliometric analysis: An overview and guidelines. Journal of Business Research133: 285–296.
20.
DusdalJPowellJJW (2021) Benefits, Motivations, and Challenges of International Collaborative Research: A Sociology of Science Case Study. Science and Public Policy48(2). Oxford Academic: 235–245.
21.
EscartinCGaleaELakatosA, et al. (2021) Reactive astrocyte nomenclature, definitions, and future directions. Nature Neuroscience24(3): 312–325.
22.
FarrellCMumfordPWisemanFK (2022) Rodent Modeling of Alzheimer’s Disease in Down Syndrome: In vivo and ex vivo Approaches. Frontiers in Neuroscience16.
23.
FekiAHibaouiY (2018) DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome. Brain Sciences8(10): 187.
24.
FernandezFMorishitaWZunigaE, et al. (2007) Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nature Neuroscience10(4): 411–413.
25.
Fernandez-MarcosPJAuwerxJ (2011) Regulation of PGC-1α, a nodal regulator of mitochondrial biogenesis. The American Journal of Clinical Nutrition93(4): 884S–890.
26.
Flores-AguilarLIulitaMFKovecsesO, et al. (2020) Evolution of neuroinflammation across the lifespan of individuals with Down syndrome. Brain: A Journal of Neurology143(12): 3653–3671.
27.
ForteaJVilaplanaECarmona-IraguiM, et al. (2020) Clinical and biomarker changes of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study. Lancet (London, England)395(10242): 1988–1997.
28.
ForteaJZamanSHHartleyS, et al. (2021) Alzheimer’s disease associated with Down syndrome: a genetic form of dementia. The Lancet. Neurology20(11): 930–942.
29.
FrankMDuvezin-CaubetSKoobS, et al. (2012) Mitophagy is triggered by mild oxidative stress in a mitochondrial fission dependent manner. Biochimica Et Biophysica Acta1823(12): 2297–2310.
30.
FrankishACarbonell-SalaSDiekhansM, et al. (2023) GENCODE: reference annotation for the human and mouse genomes in 2023. Nucleic Acids Research51(D1): D942–D949.
31.
GarcíaOFlores-AguilarL (2022) Astroglial and microglial pathology in Down syndrome: Focus on Alzheimer’s disease. Frontiers in Cellular Neuroscience16.
32.
GeYChaoTSunJ, et al. (2022) Frontiers and Hotspots Evolution in Psycho-cardiology: A Bibliometric Analysis From 2004 to 2022. Current Problems in Cardiology47(12): 101361.
33.
GensousNBacaliniMGFranceschiC, et al. (2020) Down syndrome, accelerated aging and immunosenescence. Seminars in Immunopathology42(5): 635–645.
34.
GomezWMoralesRMaracaja-CoutinhoV, et al. (2020) Down syndrome and Alzheimer’s disease: common molecular traits beyond the amyloid precursor protein. Aging12(1): 1011–1033.
35.
GuidiSBonasoniPCeccarelliC, et al. (2008) Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. Brain Pathology (Zurich, Switzerland)18(2): 180–197.
36.
HeadEAzizehBYLottIT, et al. (2001) Complement association with neurons and beta-amyloid deposition in the brains of aged individuals with Down Syndrome. Neurobiology of Disease8(2): 252–265.
37.
HeadELottITWilcockDM, et al. (2016) Aging in Down Syndrome and the Development of Alzheimer’s Disease Neuropathology. Current Alzheimer Research13(1): 18–29.
38.
HeadEHelmanAPowellD, et al. (2018) Down syndrome, beta-amyloid and neuroimaging. Free radical biology & medicine114: 102–109.
39.
HelgueraPSeiglieJRodriguezJ, et al. (2013) Adaptive downregulation of mitochondrial function in down syndrome. Cell Metabolism17(1): 132–140.
40.
HuangTFakuraziSCheahP-S, et al. (2023) REST Targets JAK-STAT and HIF-1 Signaling Pathways in Human Down Syndrome Brain and Neural Cells. International Journal of Molecular Sciences24(12): 9980.
41.
HuggardDKellyLRyanE, et al. (2020) Increased systemic inflammation in children with Down syndrome. CYTOKINE127. London: Academic Press Ltd- Elsevier Science Ltd: 154938.
42.
IulitaMFBejaninAVilaplanaE, et al. (2023) Association of biological sex with clinical outcomes and biomarkers of Alzheimer’s disease in adults with Down syndrome. Brain Communications5(2): fcad074.
43.
IzzoANittiMMolloN, et al. (2017) Metformin restores the mitochondrial network and reverses mitochondrial dysfunction in Down syndrome cells. Human Molecular Genetics26(6): 1056–1069.
44.
JørgensenOSBrooksbankBWBalázsR (1990) Neuronal plasticity and astrocytic reaction in Down syndrome and Alzheimer disease. Journal of the Neurological Sciences98(1): 63–79.
45.
KhakhBSDeneenB (2019) The Emerging Nature of Astrocyte Diversity. Annual Review of Neuroscience42(1): 187–207.
46.
KimSHVlkolinskyRCairnsN, et al. (2000) Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimer’s disease and Down syndrome. Cellular and molecular life sciences: CMLS57(12): 1810–1816.
47.
KimSHVlkolinskyRCairnsN, et al. (2001) The reduction of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer’s disease. Life Sciences68(24): 2741–2750.
48.
KingASzekelyBCalapkuluE, et al. (2020) The Increased Densities, But Different Distributions, of Both C3 and S100A10 Immunopositive Astrocyte-Like Cells in Alzheimer’s Disease Brains Suggest Possible Roles for Both A1 and A2 Astrocytes in the Disease Pathogenesis. Brain Sciences10(8). 8. Multidisciplinary Digital Publishing Institute: 503.
49.
KongX-FWorleyLRinchaiD, et al. (2020) Three Copies of Four Interferon Receptor Genes Underlie a Mild Type I Interferonopathy in Down Syndrome. Journal of Clinical Immunology40(6): 807–819.
50.
KrapfenbauerKYooBCCairnsN, et al. (1999) Differential display reveals deteriorated mRNA levels of NADH3 (complex I) in cerebellum of patients with Down syndrome. Journal of Neural Transmission. Supplementum57: 211–220.
51.
KrivegaMStiefelCMStorchovaZ (2022) Consequences of chromosome gain: A new view on trisomy syndromes. The American Journal of Human Genetics109(12). Elsevier: 2126–2140.
52.
LinnerbauerMWheelerMAQuintanaFJ (2020) Astrocyte Crosstalk in CNS Inflammation. Neuron108(4). Elsevier: 608–622.
53.
LiuLLiuJBaoJ, et al. (2020) Interaction of Microglia and Astrocytes in the Neurovascular Unit. Frontiers in Immunology11.
54.
LuJEspositoGScuderiC, et al. (2011) S100B and APP Promote a Gliocentric Shift and Impaired Neurogenesis in Down Syndrome Neural Progenitors. PLOS ONE6(7). Public Library of Science: e22126.
55.
LuTAronLZulloJ, et al. (2014) REST and stress resistance in ageing and Alzheimer’s disease. Nature507(7493): 448–454.
56.
MampayMSheridanGK (2019) REST: An epigenetic regulator of neuronal stress responses in the young and ageing brain. Frontiers in Neuroendocrinology53: 100744.
57.
MatthewsKAXuWGagliotiAH, et al. (2019) Racial and ethnic estimates of Alzheimer’s disease and related dementias in the United States (2015-2060) in adults aged ≥65 years. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association15(1): 17–24.
58.
McCarronMMcCallionPReillyE, et al. (2017) A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome. Journal of intellectual disability research: JIDR61(9): 843–852.
59.
MinersJSJonesRLoveS (2014) Differential changes in Aβ42 and Aβ40 with age. Journal of Alzheimer’s disease: JAD40(3): 727–735.
60.
MolloNNittiMZerilloL, et al. (2019) Pioglitazone Improves Mitochondrial Organization and Bioenergetics in Down Syndrome Cells. Frontiers in Genetics10: 606.
61.
Nakano-KobayashiAAwayaTKiiI, et al. (2017) Prenatal neurogenesis induction therapy normalizes brain structure and function in Down syndrome mice. Proceedings of the National Academy of Sciences of the United States of America114(38): 10268–10273.
62.
OrtegaMDe TomaIFernández-BlancoÁ, et al. (2022) Proteomic profiling reveals mitochondrial dysfunction in the cerebellum of transgenic mice overexpressing DYRK1A, a Down syndrome candidate gene. Frontiers in Molecular Neuroscience15: 1015220.
63.
PeiZChenSDingL, et al. (2022) Current perspectives and trend of nanomedicine in cancer: A review and bibliometric analysis. Journal of Controlled Release352: 211–241.
64.
PinterJDBrownWEEliezS, et al. (2001) Amygdala and hippocampal volumes in children with Down syndrome: a high-resolution MRI study. Neurology56(7): 972–974.
65.
PintoBMorelliGRastogiM, et al. (2020) Rescuing Over-activated Microglia Restores Cognitive Performance in Juvenile Animals of the Dp(16) Mouse Model of Down Syndrome. Neuron108(5): 887-904.e12.
66.
Ponroy BallyBMuraiKK (2021) Astrocytes in Down Syndrome Across the Lifespan. Frontiers in Cellular Neuroscience15: 702685.
67.
PowersRKCulp-HillRLudwigMP, et al. (2019) Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors. Nature Communications10: 4766.
68.
RammohanMBhansaliRSTsaiY-C, et al. (2018) STAT3 Is Activated By DYRK1A and Is a Potential Therapeutic Target in B-ALL. Blood132: 3898.
69.
ReicheLKüryPGöttleP (2019) Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?Cells8(12): 1591.
70.
ReicheLGöttlePLaneL, et al. (2021) C21orf91 Regulates Oligodendroglial Precursor Cell Fate—A Switch in the Glial Lineage?Frontiers in Cellular Neuroscience15: 653075.
71.
RusuBKukrejaBWuT, et al. (2023) Single-Nucleus Profiling Identifies Accelerated Oligodendrocyte Precursor Cell Senescence in a Mouse Model of Down Syndrome. eNeuro10(8). Society for Neuroscience.
72.
SawaMOverkCBeckerA, et al. (2022) Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association18(6): 1203–1234.
73.
SimmonsECScholpaNESchnellmannRG (2020) Mitochondrial biogenesis as a therapeutic target for traumatic and neurodegenerative CNS diseases. Experimental Neurology329: 113309.
74.
StagniFBartesaghiR (2022) The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives. Frontiers in Cellular Neuroscience16: 903729.
75.
StagniFGiacominiAEmiliM, et al. (2018) Neurogenesis impairment: An early developmental defect in Down syndrome. Free Radical Biology & Medicine114: 15–32.
76.
SynnestvedtMBChenCHolmesJH (2005) CiteSpace II: Visualization and Knowledge Discovery in Bibliographic Databases. AMIA Annual Symposium Proceedings2005: 724–728.
77.
TrazziSFuchsCDe FranceschiM, et al. (2014) APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiology of Disease67: 24–36.
78.
ValentiDRossiLMarzulliD, et al. (2017) Inhibition of Drp1-mediated mitochondrial fission improves mitochondrial dynamics and bioenergetics stimulating neurogenesis in hippocampal progenitor cells from a Down syndrome mouse model. Biochimica Et Biophysica Acta. Molecular Basis of Disease1863(12): 3117–3127.
79.
van EckNJWaltmanL (2010) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics84(2): 523–538.
80.
VilardellMRascheAThormannA, et al. (2011) Meta-analysis of heterogeneous Down Syndrome data reveals consistent genome-wide dosage effects related to neurological processes. BMC genomics12: 229.
81.
WeickJPHeldDLBonadurerGF, et al. (2013) Deficits in human trisomy 21 iPSCs and neurons. Proceedings of the National Academy of Sciences of the United States of America110(24): 9962–9967.
82.
WhalleyK (2020) Microglia drive dysfunction in Down syndrome. Nature Reviews Neuroscience21(12). 12. Nature Publishing Group: 667–667.
83.
WilcockDMHurbanJHelmanAM, et al. (2015) Down syndrome individuals with Alzheimer’s disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer’s disease. Neurobiology of Aging36(9): 2468–2474.
84.
WisemanFKAl-JanabiTHardyJ, et al. (2015) A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nature Reviews. Neuroscience16(9): 564–574.
85.
WuFGaoJKangJ, et al. (2022) Knowledge Mapping of Exosomes in Autoimmune Diseases: A Bibliometric Analysis (2002-2021). Frontiers in Immunology13: 939433.
86.
ZampieriBLCostaACS (2022) Evidence of Energy Metabolism Alterations in Cultured Neonatal Astrocytes Derived from the Ts65Dn Mouse Model of Down Syndrome. Brain Sciences12(1): 83.
87.
ZdaniukGWierzba-BobrowiczTSzpakGM, et al. (2011) Astroglia disturbances during development of the central nervous system in fetuses with Down’s syndrome. Folia Neuropathologica49(2): 109–114.
88.
ZengAFanYDiZ, et al. (2022) Impactful scientists have higher tendency to involve collaborators in new topics. Proceedings of the National Academy of Sciences 119(33). Proceedings of the National Academy of Sciences: e2207436119.
89.
ZerbinoDRAchuthanPAkanniW, et al. (2018) Ensembl 2018. Nucleic Acids Research46(D1): D754–D761.
90.
ZhaoYPogueAILukiwWJ (2015) MicroRNA (miRNA) Signaling in the Human CNS in Sporadic Alzheimer’s Disease (AD)-Novel and Unique Pathological Features. International Journal of Molecular Sciences16(12): 30105–30116.
91.
ZouL-HShiY-JHeH, et al. (2019) Effects of FGF2/FGFR1 Pathway on Expression of A1 Astrocytes After Infrasound Exposure. Frontiers in Neuroscience13.
